Menu Search
Equities

Ikonisys SA

9W8:STU

Ikonisys SA

Actions
  • Price (EUR)1.40
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+0.72%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ikonisys SA is a France-based that specialize in the design, manufacture and marketing of medical diagnostic equipment. The Company offers cell diagnostic products in the fields of cancer diagnosis, detection of genetic disorders, and fertility testing. It utilizes advanced molecular and immunological markers, Ikoniscope robotic components, software engine, image acquisition, digital microscope and cell detection to design and deliver accurate and reliable detection of rare cells. It includes clinical diagnostic applications for the diagnosis of different types of cancer, including bladder (oncoFISH bladder), breast (oncoFISH her2), cervical (oncoFISH cervical), prostate (oncoFISH PTEN), lung (oncoFISH ALK) and a variety of hematological cancers utilizing the Explorer applications.

  • Revenue in EUR (TTM)617.19k
  • Net income in EUR-2.70m
  • Incorporated2021
  • Employees10.00
  • Location
    Ikonisys SA62 Rue De Caumartin, Paris 9PARIS 75009FranceFRA
  • Phone+33 144710014
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ALIKO:PAR since
announced		Transaction
value
Hospitex International SrlAnnounced30 Nov 202330 Nov 2023Announced4.26%3.87m
Data delayed at least 15 minutes, as of Nov 14 2024 10:32 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.